Revvity Unveils Cancer Research Innovations at AACR Conference

Got story updates? Submit your updates here. ›

Revvity, Inc., a leading biotech firm based in Waltham, Massachusetts, is showcasing its newest innovations in cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The conference, running from April 17-22, brings together top researchers, clinicians, and industry leaders to share the latest advancements in the fight against cancer.

Why it matters

As a major player in the cancer research space, Revvity's participation in the AACR conference underscores the company's commitment to developing cutting-edge tools and solutions that can accelerate scientific discoveries and improve patient outcomes. The annual meeting provides a valuable platform for Revvity to engage with the broader cancer research community and demonstrate how its technologies are driving progress in this critical field.

The details

Revvity, which is headquartered in Waltham, Massachusetts, will be highlighting its latest cancer research innovations at various sessions and exhibits throughout the AACR conference. The company's product portfolio includes a range of specialized instruments, software, and consumables designed to support advanced cancer studies, from genomic analysis to drug discovery.

• The AACR Annual Meeting 2026 will take place from April 17-22 in San Diego.
• Revvity has been a regular participant at the AACR conference for the past decade, showcasing its evolving cancer research solutions.

What’s next

The AACR conference will provide a valuable opportunity for Revvity to connect with researchers, clinicians, and industry peers, fostering new collaborations and exploring ways to further enhance its cancer research offerings.